MAPT and amyloidosis: Regarding the sequence of biomarkers by sex, the study conducted on the DABNI and UK cohorts (Iulita et al., 2023) found that males and females exhibit similar trajectories with age for markers of amyloidosis (CSF amyloid-β 42/40 and amyloid-PET), tau pathology (CSF and plasma phosphorylated-tau181), and neurodegeneration (CSF and plasma neurofilament light, total-tau, fluorodeoxyglucose-PET, and MRI).